Clinical Research Papers:
Survival following segmentectomy or lobectomy in elderly patients with early-stage lung cancer
Metrics: PDF 1234 views | HTML 1088 views | ?
Yang Zhang1,2,*, Chongze Yuan1,2,*, Yawei Zhang1,2, Yihua Sun1,2, Haiquan Chen1,2,3,4
1Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
3Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
4Institutes of Biomedical Sciences, Fudan University, Shanghai, China
* These authors have contributed equally to this work
Haiquan Chen, e-mail: email@example.com
Yihua Sun, e-mail: Sun_yihua76@hotmail.com
Keywords: non-small cell lung cancer, lobectomy, segmentectomy
Received: October 05, 2015 Accepted: February 06, 2016 Published: February 25, 2016
Purpose: To determine the survival following segmentectomy versus lobectomy in elderly patients with early-stage non-small cell lung cancer (NSCLC).
Methods: We identified 12324 elderly (≥ 70 years) patients with stage I ≤ 3 cm NSCLC in the Surveillance, Epidemiology and End Results (SEER) database. Propensity score methods were used to balance baseline characteristics of patients undergoing segmentectomy or lobectomy. Overall survival (OS) and lung cancer-specific survival (LCSS) of patients treated with segmentectomy versus lobectomy were compared in Cox regression models after adjusting, stratifying or matching patients based on propensity scores.
Results: Cox models adjusting, stratifying or matching propensity scores all showed that patients treated with segmentectomy had significantly worse OS and LCSS compared to lobectomy. Subgroup analysis of patients with tumors ≤ 2cm, aged ≥ 75 years, or had ≥ 7 lymph nodes examined also revealed survival advantage associated with lobectomy.
Conclusion: Elder age alone could not justify the application of segmentectomy in early-stage lung cancer. Prospective randomized trials are warranted to validate our results.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.